ArticleJournal of signal transduction2012
Antiangiogenic therapy for glioma.
Article in Journal of signal transduction, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- The immunoregulatory role of integrins in pulmonary diseases.Frontiers in immunology · 2025Review
- Mocetinostat as a novel selective histone deacetylase (HDAC) inhibitor in the promotion of apoptosis in glioblastoma cell line C6 and T98G.Research square · 2024Article
- The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy.Cancers · 2021Review
- Caveolin-1 promotes tumor cell proliferation and vasculogenic mimicry formation in human glioma.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- Overexpression of HOXC10 promotes angiogenesis in human glioma via interaction with PRMT5 and upregulation of VEGFA expression.Theranostics · 2018Article
- Downregulation of LRIG2 expression inhibits angiogenesis of glioma via EGFR/VEGF-A pathway.Oncology letters · 2017Article
- Long non-coding RNA HOTAIR enhances angiogenesis by induction of VEGFA expression in glioma cells and transmission to endothelial cells via glioma cell derived-extracellular vesicles.American journal of translational research · 2017Article
- Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma.Annals of translational medicine · 2016Review
- VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme.Journal of neuro-oncology · 2015Article
- Adaptation to antiangiogenic therapy in neurological tumors.Cellular and molecular life sciences : CMLS · 2015Review
- OKN-007 decreases VEGFR-2 levels in a preclinical GL261 mouse glioma model.American journal of nuclear medicine and molecular imaging · 2015Article
- Therapeutic effects of LS-13 on glioma in vivo and in vitro.CNS neuroscience & therapeutics · 2014Article
- Article
- TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013Article
- Anti-cancer Therapies in High Grade Gliomas.Current proteomics · 2013Article
- Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme.Journal of molecular medicine (Berlin, Germany) · 2013Review
- Angiogenesis and its therapeutic opportunities.Mediators of inflammation · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, antiangiogenic agents are routinely used for the treatment of patients with glioma. However, despite advances in pharmacological and surgical therapy, glioma remains an incurable disease. Indeed, the formation of an abnormal tumor vasculature and the invasion of glioma cells along neuronal tracts are proposed to comprise the major factors that are attributed to the therapeutic resistance of these tumors. The development of curative therapeutic modalities for the treatment of glioma requires further investigation of the molecular mechanisms regulating angiogenesis and invasion. In this review, we discuss the molecular characteristics of angiogenesis and invasion in human malignant glioma, we present several available drugs that are used or can potentially be utilized for the inhibition of angiogenesis in glioma, and we focus our attention on the key mediators of the molecular mechanisms underlying the resistance of glioma to antiangiogenic therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.